Skip to main content
padlock icon - secure page this page is secure

Computational Approaches for Fragment Optimization

Buy Article:

$68.00 + tax (Refund Policy)

Fragment based screening has become a valuable tool to complement traditional lead finding methods like high throughput screening in drug discovery. Fragments are low molecular mass compounds and are usually screened using high sensitivity biophysical methods which are suitable for the detection of weakly binding ligands. Because fragments have a low affinity, efficient methods to improve their affinity are required. Structure based methods, i.e. methods which make use of a three dimensional structure of the protein have been applied in most of the cases for fragment optimization programs which are reported in the literature. De novo design, combinatorial docking and interactive optimization fell in this category and belong to the computer-aided drug design field. While de novo design is a computational method where a ligand is build completely de novo, combinatorial docking is applied to evaluate easily accessible or physically existing compound libraries around a previously identified core and interactive optimization alternates computational, biological and structural experiments to progress towards a drug. The principles, advantages, drawbacks of the different methods are being discussed together with examples of applications taken from the literature. At the end of the article we define a new metric to express the efficiency of optimization and show that small molecular molecules, i.e. fragments with a molecular mass below 250 Da, tend to be more easily optimized than larger molecules, thus reinforcing the interest of the fragment approach in the drug discovery process.

No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Fragment optimization; combinatorial docking; de novo design; hit to lead optimization; structure based drug design

Document Type: Research Article

Affiliations: Expertise Platform Protease,Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.

Publication date: March 1, 2007

More about this publication?
  • Current Computer-Aided Drug Design aims to publish all the latest developments in drug design based on computational techniques. The field of computer-aided drug design has had extensive impact in the area of drug design. Current Computer-Aided Drug Design is an essential journal for all medicinal chemists who wish to be kept informed and up-to-date with all the latest and important developments in computer-aided methodologies and their applications in drug discovery. Each issue contains a series of timely, in-depth reviews written by leaders in the field, covering a range of computational techniques for drug design, screening, ADME studies, etc., providing excellent rationales for drug development.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more